Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States

被引:263
|
作者
Kim, Donghee [1 ]
Konyn, Peter [2 ]
Sandhu, Keeryth K. [1 ]
Dennis, Brittany B. [3 ]
Cheung, Amanda C. [1 ]
Ahmed, Aijaz [1 ]
机构
[1] Stanford Univ, Div Gastroenterol & Hepatol, Sch Med, 300 Pasteur Dr, Stanford, CA 94304 USA
[2] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94304 USA
[3] Master Univ, Dept Med, Hamilton, ON L8S 4L8, Canada
关键词
hepatic steatosis; NHANES; death; cardiovascular; malignancy; FIBROSIS; NAFLD;
D O I
10.1016/j.jhep.2021.07.035
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Recently, international experts proposed redefining non-alcoholic fatty liver disease (NAFLD) as metabolic dysfunction-associated fatty liver disease (MAFLD), based on modified criteria. It is suspected that outcomes such as mortality may differ for these clinical entities. We studied the impact of MAFLD and NAFLD on all-cause and cause-specific mortality in US adults. Methods: We analyzed data from 7,761 participants in the Third National Health and Nutrition Examination Survey and their linked mortality through 2015. NAFLD was diagnosed by ultrasonographic evidence of hepatic steatosis without other known liver diseases. MAFLD was defined based on the criteria proposed by an international expert panel. The Cox proportional hazard model was used to study all-cause mortality and cause-specific mortality between MAFLD and NAFLD, with adjustments for known risk factors. Results: During a median follow-up of 23 years, individuals with MAFLD had a 17% higher risk of all-cause mortality (hazard ratio [HR] 1.17; 95% CI 1.04-1.32). Furthermore, MAFLD was associated with a higher risk of cardiovascular mortality. NAFLD per se did not increase the risk of all-cause mortality. Individuals who met both definitions had a higher risk of all-cause mortality (HR 1.13, 95% CI 1.00-1.26), while individuals who met the definition for MAFLD but not NAFLD had a 1.7-fold higher risk of all-cause mortality (HR 1.66, 95% CI 1.19-2.32). Estimates for all-cause mortality were higher for those with advanced fibrosis and MAFLD than for those with advanced fibrosis and NAFLD. Conclusions: In this US population-based study, MAFLD was associated with an increased risk of all-cause mortality, while NAFLD demonstrated no association with all-cause mortality after adjusting for metabolic risk factors. Lay summary: Our findings provide further support for the idea that non-alcoholic fatty liver disease (NAFLD) is a part of a broader multi-system disease that also includes obesity, diabetes, high blood pressure, and high cholesterol. Therefore, re defining NAFLD as metabolic dysfunction-associated fatty liver disease (MAFLD) may help improve our understanding of predictors that increase the risk of death. (C) 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1284 / 1291
页数:9
相关论文
共 50 条
  • [1] Metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality among adults in the United States
    Kim, Donghee
    Wijarnpreecha, Karn
    Cholankeril, George
    Ahmed, Aijaz
    [J]. JOURNAL OF HEPATOLOGY, 2024, 80 (02)
  • [2] Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort
    Cheng, Wei-Chun
    Chen, Hua-Fen
    Cheng, Hsiu-Chi
    Li, Chung-Yi
    [J]. EPIDEMIOLOGY AND HEALTH, 2024, 46
  • [3] Are there all-cause mortality differences between metabolic dysfunction-associated steatotic liver disease subtypes?
    Li, Mengqi
    Xie, Wen
    [J]. JOURNAL OF HEPATOLOGY, 2024, 80 (02) : e53 - e54
  • [4] Nonalcoholic Fatty Liver Disease, Metabolic Dysfunction Associated Fatty Liver Disease, and Associations with All-Cause and Cause Specific Mortality
    Huang, Qi
    Zou, Xiantong
    Zhou, Xianghai
    Ji, Linong
    [J]. DIABETES, 2021, 70
  • [5] Letter: metabolic dysfunction-associated fatty liver disease increases risk of all-cause mortality in patients with chronic hepatitis C
    Zhao, Qianwen
    Deng, Yunlei
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (02) : 272 - 273
  • [6] Trends in the Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in the United States
    Wong, Robert J.
    Cheung, Ramsey
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (03) : E610 - E613
  • [7] Association of Metabolic Dysfunction-Associated Fatty Liver Disease with Cognitive Impairment and All-Cause Dementia: A Comprehensive Review
    Kaya, Eda
    Yilmaz, Yusuf
    [J]. TURKISH JOURNAL OF GASTROENTEROLOGY, 2024, 35 (02):
  • [8] Estimated pulse wave velocity in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
    Kim, Donghee
    Manikat, Richie
    Wijarnpreecha, Karn
    Cholankeril, George
    Ahmed, Aijaz
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024,
  • [9] Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease
    Min, Yu
    Wei, Xiaoyuan
    Wei, Zhigong
    Song, Ge
    Zhao, Xin
    Lei, Yi
    [J]. CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [10] FERRITIN IS ASSOCIATED WITH INCREASED MORTALITY, PROGRESSION TO CIRRHOSIS, AND DEVELOPMENT OF CARDIOVASCULAR DISEASE IN METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE
    Suresh, Deepika
    Miller, Matthew
    Wijarnpreecha, Karn
    Chen, Vincent
    [J]. HEPATOLOGY, 2022, 76 : S714 - S715